MENU
Go to the list of all blogs
Allana's Avatar
published in Blogs
May 17, 2019
Five states to join lawsuit of OxyContin maker Purdue Pharma

Five states to join lawsuit of OxyContin maker Purdue Pharma

Five U.S. states filed lawsuits accusing Purdue Pharma of illegally marketing and selling opioids, escalating the wave of litigation over a nationwide abuse epidemic. Iowa, Kansas, Maryland, West Virginia and Wisconsin joined 39 states to file lawsuits targeting Purdue Pharma and its leaders, including former president Richard Sackler and his family. 

Officials accused Purdue Pharma of repeatedly making false and deceptive claims that opioids, including OxyContin, were safe for a wide range of patients seeking to reduce pain. 

Purdue Pharma called the new lawsuits “misleading attacks.” “These complaints are part of a continuing effort to try these cases in the court of public opinion rather than the justice system,” the Stamford, Connecticut-based company said.

Related Ticker: FTXH

FTXH in +4.12% Uptrend, rising for three consecutive days on June 26, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where FTXH advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Aroon Indicator entered an Uptrend today. In of 277 cases where FTXH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for FTXH moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FTXH as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FTXH turned negative on July 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTXH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FTXH broke above its upper Bollinger Band on June 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), ZOETIS (NYSE:ZTS).

Industry description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals TM Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Market Cap

The average market capitalization across the First Trust Nasdaq Pharmaceuticals ETF ETF is 65.09B. The market cap for tickers in the group ranges from 1.47B to 1.02T. LLY holds the highest valuation in this group at 1.02T. The lowest valued company is PRGO at 1.47B.

High and low price notable news

The average weekly price growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF ETF was 8%. For the same ETF, the average monthly price growth was 25%, and the average quarterly price growth was 132%. CORT experienced the highest price growth at 7%, while SRPT experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF ETF was -1%. For the same stocks of the ETF, the average monthly volume growth was -71% and the average quarterly volume growth was -36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 57
Price Growth Rating: 39
SMR Rating: 65
Profit Risk Rating: 60
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
FTXH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Wheaton
Phone
N/A
Web
www.ftportfolios.com